Article

CK a safe modality for hyperopia, hyperopic astigmatism after cataract

San Francisco-Limited off-label experience indicates that conductivekeratoplasty (CK) is an effective and highly safe modality for reducinglow levels of hyperopia and hyperopic astigmatism present in patients followingcataract/IOL surgery, said Louis D. Nichamin, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
Related Content
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
July 10th 2025

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
July 10th 2025

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Precautionary recall announced for specific batch of Zaditen eye drops in the UK
July 8th 2025

Precautionary recall announced for specific batch of Zaditen eye drops in the UK

Health Canada approves aflibercept biosimilar Aflivu
July 8th 2025

Health Canada approves aflibercept biosimilar Aflivu

© 2025 MJH Life Sciences

All rights reserved.